Сравнение

Amycretin vs. Pemvidutide

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

Pemvidutide

The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследование на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Amycretin	Pemvidutide
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Frequently asked questions

What is the difference between Amycretin and Pemvidutide?: Amycretin is classified as "Метаболизм", while Pemvidutide is classified as "Метаболизм". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or Pemvidutide?: The highest available evidence level is "РКИ на людях" for Amycretin and "Исследование на людях" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and Pemvidutide in Germany and the United States?: Германия: Amycretin — Не одобрено, Pemvidutide — Не одобрено. США: Amycretin — Не одобрено, Pemvidutide — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

Pemvidutide

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between Amycretin and Pemvidutide?

Amycretin is classified as "Метаболизм", while Pemvidutide is classified as "Метаболизм". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or Pemvidutide?

The highest available evidence level is "РКИ на людях" for Amycretin and "Исследование на людях" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and Pemvidutide in Germany and the United States?

Германия: Amycretin — Не одобрено, Pemvidutide — Не одобрено. США: Amycretin — Не одобрено, Pemvidutide — Не одобрено. These are factual summaries with source and review date on the individual pages.